| Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39288737无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| The efficacy of keverprazan-based quadruple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind, multicentre trial.Int J Antimicrob Agents | PMID 39293772无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 39298144PMC11413752 | 2024-Nov | 0.95 | The study meets all criteria except for the requirement of a drug-containing intervention. The intervention is stereotactic body radiotherapy vs hypofractionated conventional radiotherapy, which is a non-drug radiation therapy comparison. Therefore, it is excluded. | 待处理 |
| Association of Serum Biomarkers With Neurocognitive Decline After PCI in Small Cell Lung Cancer: An Exploratory Study of the Phase III NCT01780675 Trial.Clin Lung Cancer | PMID 39304362无 PMCID | 2024-Nov | 0.85 | The record is a secondary biomarker analysis from a definitive Phase III RCT in oncology but does not report any survival, progression, recurrence, death, hazard, or time-to-event efficacy outcome, which is required for inclusion. | 待处理 |
| Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.Lancet Neurol | PMID 39307151无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.Lancet Neurol | PMID 39307154无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.Diabetes Obes Metab | PMID 39308336无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Nat Med | PMID 39313594PMC11564101 | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.J Dermatol | PMID 39328096无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study.J Dermatol | PMID 39328126无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The immunotherapy-based combination associated score as a robust predictor for outcome and response to combination of immunotherapy and VEGF inhibitors in renal cell carcinoma.Comput Biol Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39341105无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.J Infect | PMID 39341405无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.Circ Heart Fail | PMID 39342655PMC11573060 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy.Jpn J Ophthalmol | PMID 39356386无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of YOCAS©® yoga on cancer-related fatigue and quality of life in older (60+) vs. younger (≤ 59) cancer survivors: Secondary analysis of a nationwide, multicenter, phase 3 randomized controlled trial.J Geriatr Oncol | PMID 39368335PMC11822854 | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study.Alzheimers Dement | PMID 39369280PMC11567808 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.CNS Drugs | PMID 39373844PMC11486793 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.Ann Intern Med | PMID 39374532PMC11573625 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1.Lancet Diabetes Endocrinol | PMID 39374601无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study.Curr Med Res Opin | PMID 39378042无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With Endometriosis-Associated Pain: Two Replicate Phase 3, Randomised, Double-Blind, Studies (SPIRIT 1 and 2).J Obstet Gynecol Neonatal Nurs | PMID 39395815无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].ESMO Open | PMID 39418883PMC11532431 | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study.United European Gastroenterol J | PMID 39452892PMC11578847 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial.J Gynecol Oncol | PMID 39453395PMC11543249 | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.Cancer Med | PMID 39527466PMC11552649 | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.Clin Transl Sci | PMID 39533519PMC11557512 | 2024-Nov | 0.95 | The study is oncology, human, randomized, Phase III, and has a drug intervention. However, it is a secondary pharmacokinetic-pharmacodynamic analysis of QT interval prolongation, which is a safety endpoint, not a time-to-event efficacy endpoint. Therefore, it does not meet the inclusion criteria for the cohort. | 待处理 |
| Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial.JCO Glob Oncol | PMID 39541562无 PMCID | 2024-Nov | 0.95 | The study is a randomized, Phase III oncology trial with a drug intervention and reports original results. However, it is ineligible for this cohort because it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or any Kaplan-Meier/HR analysis. The endpoints reported are response rates (DCR, ORR) and safety, which do not meet the cohort's inclusion criteria. | 待处理 |
| Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.Circ Cardiovasc Imaging | PMID 39561225无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 38832972无 PMCID | 2024-Oct-31 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.Blood | PMID 39082668PMC11551846 | 2024-Oct-31 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.N Engl J Med | PMID 39476339无 PMCID | 2024-Oct-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of n-3 PUFA-Enriched vs. Olive-Oil-Based Lipid Emulsion on Oxidative Stress and Inflammatory Response in Critically Ill Post-Surgery Adults: Secondary Analysis of a Randomized Controlled Trial.Int J Mol Sci | PMID 39519287PMC11546187 | 2024-Oct-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.Nat Commun | PMID 39477924PMC11526018 | 2024-Oct-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).Int J Mol Sci | PMID 39519198PMC11545844 | 2024-Oct-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Long-term follow-up of the conventional versus no-touch isolation technique for resection of primary colon cancer (JCOG1006): randomized clinical trial.BJS Open | PMID 39602807PMC11602131 | 2024-Oct-29 | 0.85 | The study is a Phase III randomized trial in oncology (colon cancer) with a primary time-to-event endpoint (disease-free survival). However, it compares two surgical techniques, not a drug-containing intervention versus control, and thus does not meet the drug-intervention criterion. | 待处理 |
| Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial.Heart | PMID 39401872无 PMCID | 2024-Oct-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39426385无 PMCID | 2024-Oct-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 38924756无 PMCID | 2024-Oct-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.N Engl J Med | PMID 39225278无 PMCID | 2024-Oct-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).Vaccine | PMID 39241352无 PMCID | 2024-Oct-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.J Immunother Cancer | PMID 39455094PMC11529747 | 2024-Oct-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.Signal Transduct Target Ther | PMID 39438467PMC11496732 | 2024-Oct-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.BMJ | PMID 39442958PMC11497771 | 2024-Oct-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.Blood Adv | PMID 38968156PMC11493191 | 2024-Oct-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial.Sci Rep | PMID 39438591PMC11496495 | 2024-Oct-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.Ann Rheum Dis | PMID 38955475PMC11503126 | 2024-Oct-21 | 0.95 | This is a Phase III randomized trial of olokizumab plus methotrexate for rheumatoid arthritis, not a human malignant neoplasm (cancer) trial. The primary efficacy endpoints are disease activity measures (ACR20/50/70, DAS28, CDAI, SDAI, HAQ-DI, Boolean remission), not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) for an oncology indication. | 待处理 |
| Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.Ann Rheum Dis | PMID 39159997PMC11503042 | 2024-Oct-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of Gepirone-ER on Sexual Function in Patients With Major Depressive Disorder.J Clin Psychiatry | PMID 39431906PMC11495846 | 2024-Oct-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 10 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:非 KM 图;FIG 4.:非 KM 图;FIG A1.:研究设计图;另有 5 张未列出。 | PMID 38857463PMC11469630 | 2024-Oct-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| [Efficacy evaluation of extending or switching to tenofovir amibufenamide in patients with chronic hepatitis B: a phase Ⅲ randomized controlled study].Zhonghua Gan Zang Bing Za Zhi | PMID 39528323PMC12677290 | 2024-Oct-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |